| Autor: |
Pignolo, Robert J, Hsiao, Edward C, Mukaddam, Mona Al, Baujat, Geneviève, Berglund, Staffan K, Brown, Matthew A, Cheung, Angela M, Cunto, Carmen De, Delai, Patricia, Haga, Nobuhiko, Kannu, Peter, Keen, Richard, Quan Sang, Kim-Hanh Le, Mancilla, Edna E, Marino, Rose, Strahs, Andrew, Kaplan, Frederick S |
| Zdroj: |
Future Rare Diseases; January 2023, Vol. 3 Issue: 1 |
| Abstrakt: |
Plain Language SummaryThis is a plain language summary of an article originally published in the Journal of Bone and Mineral Research. People with fibrodysplasia ossificans progressiva (FOP) become physically disabled over time as new bone forms in places where it is not usually found, such as in muscles and ligaments. Until recently, there were no treatments for FOP that had been proven through clinical trials; however, a drug called palovarotene has been tested in clinical trials and may be effective. Here, we describe the MOVE trial, which investigated how effectively palovarotene works, as well as its safety in treating patients with FOP.What were the results?Results from MOVE suggest that palovarotene may reduce extra bone formation outside the normal skeleton. Patients with FOP who took palovarotene formed less new bone than those who did not take palovarotene. The most common side effects involved the skin, and included dryness and irritation. Some children who were still growing when they took palovarotene had a side effect that resulted in the (normal) growth of their skeleton stopping too soon.What do the results of the trial mean?Palovarotene may be a useful treatment option for FOP. Patients, caregivers, and doctors would need to consider the benefits and risks of treatment with palovarotene, particularly with growing children.Clinical Trial Registration: NCT03312634(ClinicalTrials.gov)To read the full Plain Language Summary of this article, click hereto view the PDF.Link to original article here |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
